These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17116098)

  • 1. Cost-effectiveness of migraine prevention: the case of topiramate in the UK.
    Brown JS; Papadopoulos G; Neumann PJ; Price M; Friedman M; Menzin J
    Cephalalgia; 2006 Dec; 26(12):1473-82. PubMed ID: 17116098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment.
    Brown JS; Papadopoulos G; Neumann PJ; Friedman M; Miller JD; Menzin J
    Headache; 2005 Sep; 45(8):1012-22. PubMed ID: 16109115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of topiramate in the prevention of migraines in the United States: an update.
    Brown JS; Rupnow MF; Neumann P; Friedman M; Menzin J
    Manag Care Interface; 2006 Dec; 19(12):31-8. PubMed ID: 17274479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of migraine prophylaxis on migraine-related resource use and productivity.
    Láinez MJ
    CNS Drugs; 2009 Sep; 23(9):727-38. PubMed ID: 19689164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-minimization analysis comparing topiramate with standard treatments in migraine prophylaxis.
    Ergun H; Gulmez SE; Tulunay FC
    Eur Neurol; 2007; 58(4):215-7. PubMed ID: 17827966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost.
    Silberstein SD; Feliu AL; Rupnow MF; Blount AC; Boccuzzi SJ
    Headache; 2007 Apr; 47(4):500-10. PubMed ID: 17445099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.
    Dodick DW; Freitag F; Banks J; Saper J; Xiang J; Rupnow M; Biondi D; Greenberg SJ; Hulihan J;
    Clin Ther; 2009 Mar; 31(3):542-59. PubMed ID: 19393844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two center, randomized pilot study of migraine prophylaxis comparing paradigms using pre-emptive frovatriptan or daily topiramate: research and clinical implications.
    Cady RK; Voirin J; Farmer K; Browning R; Beach ME; Tarrasch J
    Headache; 2012 May; 52(5):749-64. PubMed ID: 22188311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topiramate: new indication. Migraine prevention: best avoided.
    Prescrire Int; 2006 Aug; 15(84):132-3. PubMed ID: 16989025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial.
    Winner P; Pearlman EM; Linder SL; Jordan DM; Fisher AC; Hulihan J;
    Headache; 2005; 45(10):1304-12. PubMed ID: 16324162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom.
    Verdian L; Yi Y
    Seizure; 2010 Jan; 19(1):1-11. PubMed ID: 19942457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application.
    Yu J; Smith KJ; Brixner DI
    CNS Drugs; 2010 Aug; 24(8):695-712. PubMed ID: 20658800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial.
    Diener HC; Agosti R; Allais G; Bergmans P; Bussone G; Davies B; Ertas M; Lanteri-Minet M; Reuter U; Sánchez Del Río M; Schoenen J; Schwalen S; van Oene J;
    Lancet Neurol; 2007 Dec; 6(12):1054-62. PubMed ID: 17988947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topiramate for migraine prevention: a randomized controlled trial.
    Brandes JL; Saper JR; Diamond M; Couch JR; Lewis DW; Schmitt J; Neto W; Schwabe S; Jacobs D;
    JAMA; 2004 Feb; 291(8):965-73. PubMed ID: 14982912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topiramate for migraine prophylaxis.
    Fontebasso M
    Expert Opin Pharmacother; 2007 Nov; 8(16):2811-23. PubMed ID: 17956201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term migraine prevention with topiramate: open-label extension of pivotal trials.
    Rapoport A; Mauskop A; Diener HC; Schwalen S; Pfeil J
    Headache; 2006; 46(7):1151-60. PubMed ID: 16866719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials.
    Bussone G; Diener HC; Pfeil J; Schwalen S
    Int J Clin Pract; 2005 Aug; 59(8):961-8. PubMed ID: 16033621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, dose comparison study of topiramate for prophylaxis of basilar-type migraine in children: a pilot study.
    Lewis D; Paradiso E
    Headache; 2007; 47(10):1409-17. PubMed ID: 18052950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preventive treatment with topiramate enhances the quality of life of patients with migraine].
    Medrano V; Sempere AP; Morera-Guitart J; Fernandez-Izquierdo S; Espinosa-Martinez J
    Rev Neurol; 2006 Sep 1-15; 43(5):259-63. PubMed ID: 16941422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate.
    Schoenen J; Reuter U; Diener HC; Pfeil J; Schwalen S; Schäuble B; van Oene J
    Cephalalgia; 2010 Nov; 30(11):1290-5. PubMed ID: 20959424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.